Buy article

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

W.J. Fokkens - V. Backer - V.J. Lund - P.J. Barnes - M. Bernal-Sprekelsen - L. Bjermer - E. de Corso - D.M. Conti - M.E. Cornet - Z. Diamant - R. Djukanovic - M. Gaga - P. Gevaert - J.K. Han - C. Hopkins - G. Joos - B.N. Landis - S. Lau - S.E. Lee - J. Mullol - A.T. Peters - G.K. Scadding - S. Schneider - B. Senior - I.D. Pavord - S. Quirce - D. Ryan - M.E. Wechsler - P.W. Hellings

DOI: 10.4193/Rhin24.510

The introduction of biologics for the treatment of severe upper
and lower (type 2) airway inflammation has been a gamechanger
in the management of these diseases. Biologics are injectable
medications targeting different molecules relevant in (type
2) inflammation in patients with severe (type 2) airway diseases,
like asthma, eosinophilic chronic obstructive pulmonary disease
(COPD), chronic rhinosinusitis (CRS) and those who remain
uncontrolled despite regular treatment (1-3). After the phase 3 trials,
showing significant impact on symptoms, quality of life and
interventions like surgery (for the upper airways) and exacerbations
needing hospitalisation (for the lower airways), biologics are
now used in daily practice in many parts of the world (4, 5).
This pocket guide is aimed at all specialists treating adult patients
with severe airway disease.

Rhinology 0-0: 0-0, 0000